Company Profile

MediCrops Holding AG focuses on the marketing of medicinal cannabis preparations containing tetrahydrocannabinol (‘THC’). During the 2021 financial year, MediCrops founded a Swiss subsidiary, MediCrops Biomedical Technologies SA with headquarters in Yverdon-les-Bains, that will specialise in the production and processing of medicinal cannabis preparations. 
In addition,  a laboratory will be used for research purposes at the Biopôle SA research centre from June 2022.

To exploit the full medicinal potential of the cannabis plant, we have opened our own research and development department at the  Biopôle research centre in Lausanne.

The end products are extracts, distillates and isolates of the cannabis plant for use in the pharmaceutical industry, pharmacies and hospitals. The highest quality based on the Good Manufacturing Practice (GMP) of the pharmaceutical industry and proof of laboratory work to achieve a high purity level (99.95%) is the primary objective to ensure successful audits for our customers.

MediCrops wants to exploit the full medicinal potential of the cannabis plant and make it available as a remedy to patients worldwide. We focus on the refinement of medicinal cannabis for medicinal purposes.

Our vision is for MediCrops to establish itself as a leading company in the production and development of THC-based preparations in Europe.

Our ‘Future mission’ is called MediCrops. The aim is to produce standardised cannabis based on the key pharmacological ingredient THC using a combination of stable plant genetics and an automated high-tech production process to continually produce variants with consistent cannabinoid content.

To achieve this, we work day after day with all the resources we have, and this requires leadership, management and, above all, passion.



MediCrops positions itself at the centre of the cannabis ecosystem, sourcing raw materials from suppliers and delivering to pharmaceutical wholesalers and dispensaries.

Expanding product range

As a full-service provider in the field of medicinal cannabinoids, we want to offer doctors a wide range of high-quality therapeutic options on a permanent basis. From these, doctors can find the right preparation for each individual patient.

Delivery reliability

Ensuring continuous delivery reliability is one of our top priorities. Patients, doctors and pharmacists trust us to supply them with our products consistently and reliably.


Due to the change in the Narcotics Act in Switzerland from mid-2022, we expect a 180° turnaround of the Swiss market with strong growth and believe that our strategy will be fully vindicated.